PDS Biotechnology is a biopharmaceutical company specializing in the development of innovative cancer immunotherapies and infectious disease vaccines. The company operates in the biotechnology sector, focusing on creating transformative vaccines that harness the immune system to combat diseases. PDS Biotech's proprietary platform combines disease-specific proteins to direct the immune system to unleash powerful and targeted T cell and antibody responses, aiming to provide effective treatments for cancer and infectious diseases.

The company's business model involves the research, development, and commercialization of its pipeline products. PDS Biotech collaborates with other biotechnology firms and research institutions to co-develop and accelerate the development of its vaccine candidates. Revenue is generated through partnerships, licensing agreements, and potentially through the sale of its approved therapies.

PDS Biotech serves a diverse range of clients, including healthcare providers, research institutions, and pharmaceutical companies. The market it operates in is highly competitive and regulated, with a focus on addressing unmet medical needs in oncology and infectious diseases.

Keywords: cancer immunotherapy, infectious disease vaccines, T cell responses, antibody responses, biotechnology, transformative vaccines, oncology, infectious diseases, biopharmaceutical, research and development.